The $200,000 grant also dovetails with an existing grant under which the University of Oklahoma Health Sciences Center and Pure Vaccine Solutions aim to look for new disease-specific biomarkers for West Nile virus. Both Receptor Logic and Pure Vaccine Solutions are portfolio companies of VC shop Emergent Technologies.
Clinical Data's PGx Health division will work with researchers at the university to discover and validate variants in the Fc gamma receptor genes, which they believe could potentially predict patient response to monoclonal antibody therapies.
The company aims to tackle the two major issues in the antibody field — poor quality and too few antibodies — by defining a so-called "affome," an antibody set against all proteins in the human proteome.
Citing the FDA's handling of KRAS testing for anti-EGFR monoclonal antibodies, the report asserts that in the near term complex genetic tests such as Oncotype DX should be "performed through CLIA labs, and not held up by slow regulatory processes."